12
Participants
Start Date
April 30, 2011
Primary Completion Date
October 31, 2011
Study Completion Date
October 31, 2011
AZD5423
solution for injection, administered as intravenous infusion Corr to total dose of 250µg AZD5423
AZD5423
nebuliser suspension, inhaled via Spira, corr to approximately 300 µg lung deposited dose AZD5423
AZD5423
nebuliser suspension, inhaled via I-neb, corr to approximately 300 µg lung deposited dose AZD5423
AZD5423
nebuliser suspension to be administered orally, corr to a total dose of 1200 µg AZD5423
Research Unit, London
Lead Sponsor
AstraZeneca
INDUSTRY